Krystal Biotech (NASDAQ:KRYS) Issues Earnings Results, Beats Estimates By $0.09 EPS

Krystal Biotech (NASDAQ:KRYS) announced its quarterly earnings results on Monday. The company reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09, FiscalAI reports. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The company had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million.

Here are the key takeaways from Krystal Biotech’s conference call:

• VYJUVEK revenue rose 24% year over year to $119.2 million, with U.S. net revenue reaching $91.6 million and gross margin improving to 95%.
• U.S. commercial momentum remains strong, with more than 730 reimbursement approvals surpassing the company’s initial 60% penetration target; management sees additional opportunity among community-based and currently undiagnosed patients.
• The pipeline is advancing toward multiple catalysts, including readouts for the registrational DEB ocular study later this year, neurotrophic keratitis enrollment completion by year-end, and potential registrational starts in cystic fibrosis, Hailey-Hailey disease, and NSCLC in 2027.
• International demand and treatment volumes are increasing, but reported European and Japanese revenue was broadly flat because of accruals tied to German pricing negotiations; management expects key pricing outcomes in Germany, Italy, and Spain by year-end, while France may extend into 2027.
• Krystal ended the quarter with more than $1.1 billion in cash and investments and maintained its 2026 non-GAAP R&D and SG&A expense guidance of $175 million to $195 million.

Krystal Biotech Stock Down 0.9%

KRYS traded down $2.95 during trading on Wednesday, reaching $321.82. The company had a trading volume of 92,591 shares, compared to its average volume of 352,534. The stock has a market cap of $9.49 billion, a P/E ratio of 43.02 and a beta of 0.53. The business has a 50 day simple moving average of $340.40 and a 200-day simple moving average of $296.82. Krystal Biotech has a 52 week low of $132.31 and a 52 week high of $382.54.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock worth $8,243,923 in the last quarter. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Greenline Wealth Management LLC purchased a new stake in shares of Krystal Biotech in the fourth quarter worth approximately $34,000. UMB Bank n.a. boosted its holdings in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the period. Global Retirement Partners LLC grew its position in Krystal Biotech by 788.9% in the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after acquiring an additional 142 shares during the last quarter. Danske Bank A S bought a new position in Krystal Biotech in the 3rd quarter valued at $35,000. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of Krystal Biotech by 78.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 393 shares of the company’s stock valued at $69,000 after acquiring an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of research reports. Citigroup increased their target price on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Bank of America increased their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday. Finally, TD Cowen upped their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $361.56.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.